New Metastatic Brain Lesion Score Predicts 90-Day Survival Post-Craniotomy
Overview
A novel Metastatic Brain Lesion Score (MBLS) was developed to predict 90-day postoperative mortality in patients undergoing craniotomy for brain metastases. This score outperformed existing risk indices and was validated in an independent cohort, demonstrating its utility in surgical risk stratification.
Background
Brain metastases affect approximately 20% of cancer patients, with a subset requiring surgical resection. Existing surgical risk scores focus on general health but lack specificity for brain metastasis characteristics, limiting their predictive accuracy. Accurate risk assessment is critical for patient selection, preoperative optimization, and informed consent. This study aimed to create and validate a brain metastasis-specific severity score to forecast 90-day mortality after surgery.
Data Highlights
Characteristic
Creation Cohort (n=548)
Validation Cohort (n=318)
Average Age (years)
59.3 ± 11.8
60.8 ± 11.8
Patients >65 years
31.2%
Not specified
Male
51.8%
50%
Caucasian
90.3%
92.1%
90-day Mortality
20.8%
24.2%
Most Common Primary Malignancy
Non-small cell lung cancer
Non-small cell lung cancer
Key Findings
Significant predictors of 90-day mortality included age at surgery, reduced functional status, chronic pain medication use, deep brain nucleus/brainstem lesions, hydrocephalus or ventricular involvement, hemorrhage in metastases, and metastasis location.
Multivariable analysis identified a subset of these variables to construct the MBLS, with hydrocephalus/ventricular involvement ultimately excluded.
The MBLS demonstrated superior predictive ability compared to the modified frailty index-11 and recursive partitioning analysis scores.
The score was validated in an independent cohort of 318 patients, confirming its robustness and generalizability.
No significant difference in 90-day mortality rates was observed between the creation and validation cohorts.
Clinical Implications
The MBLS provides clinicians with a brain metastasis-specific tool to better estimate surgical risk and postoperative survival, facilitating improved patient selection and counseling. Incorporating tumor-specific characteristics alongside patient factors enhances prognostic accuracy beyond existing general surgical risk scores. This can guide decision-making and optimize perioperative management in neurosurgical oncology.
Conclusion
The Metastatic Brain Lesion Score is a validated, disease-specific index that effectively predicts 90-day mortality following craniotomy for brain metastases, outperforming traditional risk scores. Its adoption may improve surgical risk stratification and patient outcomes in this complex population.
References
Original Study -- A New Index for Assessing Lesion Severity to Forecast 90-Day Survival Rates Post-Surgery in Patients with Brain Metastases
by Daniel C. Kreatsoulas, Joanne Kim, Mark Damante, Anna Orr, Joshua Wang, Joshua Vignolles-Jeong, Maxwell Gruber, Varun Shah, Nicholas Musgrave, Russell Lonser, Daniel Prevedello, J. Bradley Elder, Douglas A. Hardesty
